In recent years, researchers studying multiple sclerosis have concluded that white matter lesion volume in the brain, long ...

Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better ...

SetPoint Medical’s vagus nerve stimulator offers another treatment option for patients who do not properly respond to ...

9, 2024 — New research provides valuable insights into the brain-body immune connection identifying key communication hubs in the dural sinuses and skull bone ... Dec. 5, 2024 — Scientists ...

Discover how Treg cell dysfunction fuels inflammation in arthritis and the innovative therapies targeting this paradox for ...

The drug becomes a backup to Roche’s semorinemab (RG6100), which is licensed from AC Immune and has already ... a chance of becoming the first disease-modifying drug to be approved for the ...

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...

Ulcerative colitis is associated with dysbiosis of the gut microbiota, intestinal barrier dysfunction, and an imbalance in ...

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated ...

DMARDs. Disease-modifying antirheumatic drugs (DMARDs) are powerful medications that reduce inflammation and can stop PsA from getting worse. They are available as pills, can be self-injected or given ...